
Health Care Delivery
Latest News
Advertisement
CME Content
Advertisement
























Bristol-Myers Squibb has challenged the recently released report by the Institute for Clinical and Economic Review that evaluates the clinical and cost effectiveness of newer treatments for multiple myeloma.

How would the proposed Patient Choice, Affordability, Responsibility, and Empowerment Act affect enrollment, premiums, federal spending, and out-of-pocket costs now that an estimated 20 million Americans have become newly insured?
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Sibeprenlimab for Immunoglobulin A Nephropathy
2
Patients Face New Care Complexities as DTC Options Expand
3
Expiring ACA Subsidies and CMS Payment Models Raise Costs for Consumers and Employers
4
Louisiana Delivers Innovative Cancer Treatments, but Ensuring Access Is a Work in Progress
5













































